autologous stem-cell transplantationHodgkin's lymphomaNorton-Simon hypothesisrelapsesequential high-dose chemotherapyNature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international ...
Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leu... PURPOSE: To define the activity and feasibility of brief-duration high-intensity chemotherapy for adults with small noncleaved, non-Hodgkin's...
Hodgkin illness, non-Hodgkin lymphoma and some strong growth cancers. Stem cell treatments likewise may benefit individuals who have aplastic anemia, immunodeficiencies and acquired conditions of metabolic process.
Treatments and clinical burden among hodgkin lymphoma patients at high risk of relapse after autologous stem cell transplant: A literature reviewBonthapally, VAyyagari, RYang, HWu, E QShonukan, O
738 Accesses 3 Citations 1 Altmetric Explore all metrics Abstract Autologous stem cell transplantation (autoSCT) can achieve long-term remission in primary refractory or relapsed Hodgkin lymphoma (r/r HL); however, still up to 50% of patients relapse after autoSCT. In this retrospective analysis...
doi:10.1080/10245332.2000.11746492BrunoGabrielaV.BallesterOscarF.Hematology
CAR T细胞疗法最初是针对某些类型的血液肿瘤,特别是急性淋巴细胞性白血病(Acute Lymphoblastic Leukemia, ALL)和非霍奇金淋巴瘤(Non-Hodgkin Lymphoma, NHL)。这种疗法在一些临床试验中显示出非常有希望的结果。例如,在对于难治性或复发性ALL的儿童和成...
toward a new therapeutic target STEM CELLS IN HODGKIN LYMPHOMAKim, Seok Jin
Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and d... Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin’s lymphoma and multiple myeloma patients by plerixafor an...
After salvage chemotherapy and collection of peripheral stem cell progenitors (median CD34<sup>+</sup> cells/kg: 11 ´ 10<sup>6</sup>/kg), (n = 15) patients with aggressive non-Hodgkin's lymphoma with poor prognostic factors or refractory Hodgkin's disease (n= 9) received intensified ...